Medplus Health Services Ltd

- No explicit mention of current or future new fundraising through debt or equity is made in the provided transcript. - The management discussed ongoing operational activities, store expansions, and marketing spends but did not reference any plans for raising capital. - They emphasized controlling expenses and achieving profitability improvements without indicating any upcoming fundraising events. - No indications were given about issuing new equity or raising debt in the near term. - Investor relations contact information was provided, but no fundraising calls or updates were shared during this earnings call.

- No explicit mention of current or future capex or strategic investment plans is detailed in the provided transcript from the Q1 FY25 earnings call. - The company is focused on expanding its store network with a guidance of 600 new store openings for FY '25. - There is emphasis on the ramp-up and profitability of new stores, with 64% of stores breakeven within six months. - Marketing spends were notably high (INR 9.5 crores in Q1), mostly for promotions in Tamil Nadu and West Bengal, but this is not recurring. - No direct commentary on capital expenditure or strategic investments beyond store expansion and marketing initiatives. - Management mentioned monitoring store level ROE and profitability but did not specify capital expenditure plans.

- MedPlus expects significant growth in private label sales, currently at 15% of GMV, with a steady increase of around 1.5%-2% per quarter. - The company targets 20%+ top-line revenue growth for FY '25, with pharmacy revenue growing 24% year-on-year on a GMV basis. - Expansion continues with a target of adding around 600 new stores in FY '25, focusing on tier 2 cities and beyond, which currently contribute 36% of pharmacy revenues. - As new stores mature (less than 2 years old are ramping up), improved profitability and breakeven within 4-6 months are expected to drive volume and revenue growth. - Marketing spends are being optimized, focusing on private label brand awareness, which is expected to increase customer acceptance and sales. - The gross margin and operating EBITDA per store are expected to improve as the private label mix deepens and operational efficiencies increase.

- The company expects continued margin improvement on stores older than 12 months, with operating margin potentially rising by 0.6% after adjusting for one-time advertisement expenses. - Q1 is typically the slowest quarter; margins and earnings are anticipated to improve in subsequent quarters. - Special marketing spends of INR 9.5 crore in Q1 are non-recurring and are not expected to continue in the next two quarters, which could support margin expansion. - The private label brand growth, contributing to 15% of GMV, is expected to continue positively impacting margins but with some cannibalization affecting accretiveness. - Store expansions with planned net additions of 600 stores in FY’25 are expected to contribute to revenue growth and profitability as new stores mature. - Management maintains guidance of 20%+ top-line growth for FY’25, with gross merchandise volume (GMV)-based growth at ~23%. - Central-level operating EBITDA is improving, and store-level operating ROCE stood strong at 46.1%, indicating efficient capital use.

The provided pages of the MedPlus Health Services Limited Q1 FY'25 Earnings Conference Call transcript do not contain specific information related to the current or expected order book or pending orders. The discussion primarily focuses on store performance, private label growth, financial metrics, marketing spends, and operational details. There is no mention or data shared regarding order book status or pending orders in the extracted content. If you need details on order books or pending orders, please provide relevant pages or sections where this topic might have been discussed.